The MassVentures START program awards QDTI $100k
The MassVentures START program, a program of the Commonwealth of Massachusetts designed to support early-stage, high-growth companies in the state, has awarded QDTI a $100k grant in its 2018 program. The START program is designed to help Massachusetts technology startups to leverage their SBIR funding to grow and to continue to develop their critical technology. Further details are available from MassVentures here
NSF awards QDTI a grant to support rapid sample transfer of samples for quantum magnetic sensors
The National Science Foundation (NSF) has awarded QDTI a Phase I SBIR grant to support the development of a novel technology for transferring medical biofluid and other samples onto diamond magnetic imaging sensors. This technology will allow samples to be transferred quickly and cleanly onto an imaging sensor for a variety of high-throughput testing applications. NSF is a key federal science funding agency.
NIST awards a Phase II grant to support QDTI’s development of NV imaging to support single magnetic nanoparticle development
Following a successful Phase I SBIR research program, the National Institute of Standards and Technology (NIST), a key federal science and technology agency, has awarded QDTI a Phase II SBIR contract to continue development of a platform for high-speed single magnetic nanoparticle analysis using the company’s quantum NV diamond sensing technology. Magnetic nanoparticles and beads are a key component of many biomedical diagnostics products, but the lack of a technology allowing individual magnetic particles to be tested quickly has hindered quality control and further technical development. QDTI’s technology allows the magnetic properties of thousands of magnetic particles to be tested in parallel.
QDTI awarded NIST grant to develop single nanoparticle magnetic analysis
The National Institute of Standards and Technology (NIST) has awarded QDTI a Phase I SBIR contract to support the development of a NV imaging-based instrument for single magnetic nanoparticle analysis. Magnetic nanoparticles are used in a broad range of industries but find particularly valuable application to biomedical diagnostics and therapy. Magnetic bead products for immunoassays comprise a $1 billion market. A lack of cost-effective commercial technology for high-throughput single-particle analysis impedes robust quality control, which hinders reproducibility and novel innovative uses for magnetic particles. QDTI’s novel particle analysis system with low cost and high throughput will permit high quality, high value magnetic products to reach wider markets.
DARPA continues its support for development of QDTI’s novel NV diamond imaging technology
The Defense Advanced Research Projects Agency (DARPA) has exercised its option to continue its support to QDTI for development of the company’s Nitrogen Vacancy (NV) diamond imaging technology. DARPA has been a major supporter of the development of NV technology through its QuASAR quantum sensing program. DARPA’s decision will increase its total support to QDTI for development of the technology through the agency’s SBIR program. QDTI is using the NV imaging technology to develop a new class of ultrasensitive biomedical diagnostics suitable for a wide range of protein, cellular and nucleic acid targets.
August 14, 2016
Quantum Diamond Technologies, Inc. (QDTI), a quantum-powered instrument development company, has received a contract from the National Institute of Standards and Technologies (NIST) to develop a novel analytical and quality control instrument for manufacturing ultra-uniform magnetic nanoparticles and magnetic beads. The recent contract announcement follows on the heels of QDTI’s new results showing that its diamond-based sensor technology can provide high-throughput analysis of single magnetic particles.
This Small Business Innovation Research (SBIR) Phase I contract is the second that QDTI has received. In 2012, the instrument development company was awarded a $1.8 million contract from the Defense Advanced Research Projects Agency to develop a novel quantum technology-powered analysis and magnetic imaging device for the healthcare sector.
“This contract demonstrates the significant industry need for a rapid, analytical, ultra-sensitive detection capability for magnetic nanoparticle and bead manufacture”, said John Pena, Ph.D., Chief Executive Officer of QDTI. “We look forward to working with NIST to develop this exciting new technology and to demonstrate the commercial utility of our quantum technology platform.”
Magnetic nanoparticles and beads are used by a broad range of industries and have critical applications in biomedical research, therapeutics and diagnostics. Although these particles and beads are a $1 billion/year market, innovative and expanded applications for these particles face significant development hurdles due to the lack of a cost-effective commercial technology for effective single-particle quality control.
This NIST SBIR contract shows additional support for QDTI’s quantum technology platform to provide cutting edge magnetic analysis for an application range beyond healthcare. The company’s breakthrough method of rapid, parallelized, high-resolution magnetic field imaging permits a high-throughput, single-particle quality control approach previously unattainable.